Biopure (MM) (NASDAQ:BPURD)
Historical Stock Chart
From Jul 2019 to Jul 2024
Biopure's Stock Symbol Reverts to BPUR
CAMBRIDGE, Mass., June 27 /PRNewswire-FirstCall/ -- Biopure Corporation
(NASDAQ:BPUR) announced today that the trading symbol for its Class A common
stock will revert from BPURD to BPUR at the open of the market on Tuesday, June
28, 2005.
Biopure Corporation
Biopure Corporation develops and manufactures intravenously administered
pharmaceuticals, called oxygen therapeutics, that deliver oxygen to the body's
tissues. The company is developing Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, for a potential indication in cardiovascular ischemia
and, in collaboration with the U.S. Naval Medical Research Center, for an out-
of-hospital trauma indication. The product is approved in South Africa for
treating surgery patients who are acutely anemic and for eliminating, delaying
or reducing allogeneic red blood cell transfusions in these patients. Hemopure
has not been approved for sale in any other jurisdictions, including the United
States or the European Union. Biopure's veterinary product Oxyglobin(R)
[hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic
approved by the U.S. Food and Drug Administration and the European Commission,
is indicated for the treatment of anemia in dogs.
Contact: Douglas Sayles
Biopure Corporation
(617) 234-6826
DATASOURCE: Biopure Corporation
CONTACT: Douglas Sayles of Biopure Corporation, +1-617-234-6826,
Web site: http://www.biopure.com/
Company News On-Call: http://www.prnewswire.com/comp/131224.html